Recommended Antidepressants for Depression Treatment
For first-line treatment of major depressive disorder, select any selective serotonin reuptake inhibitor (SSRI) such as sertraline, citalopram, escitalopram, fluoxetine, or paroxetine, as all second-generation antidepressants demonstrate equivalent efficacy, with medication choice based primarily on adverse effect profiles, cost, and dosing convenience. 1
First-Line Pharmacotherapy
SSRIs (Selective Serotonin Reuptake Inhibitors)
All SSRIs show comparable efficacy for acute-phase MDD with no clinically meaningful differences in response or remission rates 1. Choose based on:
- Sertraline: Preferred for melancholia and psychomotor agitation 1
- Citalopram or Escitalopram: Preferred for older adults due to favorable side effect profile 2
- Fluoxetine, Paroxetine: Generally avoid in older adults due to higher adverse effect rates 2
Important caveat: Paroxetine carries increased risk of sexual dysfunction compared to other SSRIs 1
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
- Venlafaxine: May be superior to fluoxetine for depression with anxiety symptoms 1
- Duloxetine: Equivalent efficacy to SSRIs; consider for comorbid pain 1
Note: SNRIs show slightly higher discontinuation rates due to nausea and vomiting compared to SSRIs 2
Other Second-Generation Antidepressants
- Mirtazapine: Significantly faster onset of action (within 2 weeks) compared to SSRIs, though response rates equalize after 4 weeks 1
- Bupropion: Equivalent efficacy to SSRIs; useful alternative for patients concerned about sexual side effects
- Vortioxetine: Comparable efficacy to desvenlafaxine 3
Treatment-Resistant Depression (After First-Line Failure)
Defining Treatment Resistance
Treatment resistance requires failure of at least two antidepressants with different mechanisms of action, each administered at minimum licensed dose for at least 4 weeks, with less than 25% symptom improvement 4
Second-Step Strategies
Switching Antidepressants: The STAR*D trial demonstrated that switching to bupropion, sertraline, or venlafaxine produces symptom-free status in 1 in 4 patients, with no significant differences among these three options 1
Augmentation Strategies (in order of evidence strength):
Atypical Antipsychotics (strongest evidence) 5, 6:
- Aripiprazole
- Brexpiprazole
- Quetiapine
- Olanzapine (with fluoxetine)
- Cariprazine (note: higher discontinuation rates)
Lithium: Established augmentation agent with moderate-to-high quality evidence 5
Thyroid Hormones 5:
- Liothyronine (T3)
- Levothyroxine (T4)
Lamotrigine: Particularly for bipolar spectrum features 7
Dopamine Compounds 5:
- Modafinil
- Lisdexamfetamine
Ketamine/Esketamine: For severe treatment-resistant depression with moderate certainty evidence for response 6, 8
Critical distinction: For patients with unrecognized bipolar features (subsyndromal bipolarity is a frequent cause of treatment resistance), avoid antidepressant monotherapy. Instead, use mood stabilizers (lithium, lamotrigine) or atypical antipsychotics as primary treatment 7
Maintenance Treatment Duration
- First episode: Continue antidepressants for 4-9 months after achieving satisfactory response 1
- Two or more episodes: Consider longer-term or indefinite maintenance therapy 1
- Rationale: Meta-analysis of 31 trials supports continuation therapy to reduce relapse risk 1
Monitoring Requirements
Assess treatment response within 1-2 weeks of initiation, then regularly 1. If inadequate response after 6-8 weeks at adequate dose, modify treatment strategy 1. Approximately 38% of patients fail to respond and 54% fail to achieve remission with initial antidepressant therapy 1.
Special Populations
Older adults: Prefer citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, or bupropion. Avoid paroxetine and fluoxetine 2
Depression with anxiety: Venlafaxine may offer advantage over fluoxetine 1
Depression with pain: Duloxetine or paroxetine 1
Depression with insomnia: No significant differences among fluoxetine, nefazodone, paroxetine, or sertraline 1